. Author manuscript; available in PMC: 2021 Jul 16.

Published in final edited form as: Clin Breast Cancer. 2019 Dec 5;20(3):220–227. doi: 10.1016/j.clbc.2019.11.010

Table 4:

Biomarker Performance in identification of progression or response to therapy relative to contemporaneous RECIST criteria

Predictor	Dependent	P value
GP88	progression	0.0101
GP88	Response	0.0194
CA15-3	progression	<0.0001
CA15-3	Response	0.7316

The two biomarkers were tested for association with contemporaneous RECIST assessment of disease progression (PD) and response to therapy (R). The values of these predictors were tested for statistical significance of the difference between the two groups using the Wilcoxon test. Table 4 shows that the contemporaneous GP88 is highly significantly associated with disease progression and response while CA15–3 is only significant in conjunction with progression.